Physician feedback is extremely positive as Boston Scientific completes initial launch of TAXUS® Liberté™ paclitaxel-eluting stent system
(January 31, 2005) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has completed the initial launch of its TAXUS® Liberté™ paclitaxel-eluting coronary stent system. On January 17, the Company announced that it had launched the next-generation stent system in 18 countries. The new product is now fully launched in those countries.

Early physician feedback has been extremely positive, including reaction from physicians doing live cases at the 14th Annual Singapore LIVE course.

"I had the opportunity to use the new TAXUS Liberté stent system during the recent Singapore LIVE course," said Maurice Buchbinder, M.D., of the Foundation for Cardiovascular Medicine in San Diego. "Despite somewhat challenging anatomy, the TAXUS Liberté stent system performed very nicely, crossing the lesions with ease and conforming to the anatomy very well. The angiographic results were superb. The TAXUS Liberté stent system is a significant advance in drug-eluting stent platform technology, which will enhance percutaneous therapy for more complex coronary anatomy."

"We are pleased that the feedback has been so positive on this next-generation technology," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "The innovative design of the Liberté stent significantly improves deliverability and conformability, and paclitaxel is well-known for its safety and efficacy. The TAXUS Liberté stent system is an important advance in the treatment of coronary artery disease."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

This press release contains forward-looking statements. The Company wishes to caution the reader that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with the regulatory process, introduction of new products, intellectual property, litigation, competitive product offerings and other factors described in the Company's filings with the Securities and Exchange Commission.